FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/01/101340 [Registered on: 16/01/2026] Trial Registered Prospectively
Last Modified On: 15/01/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Process of Care Changes 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Lung Ultrasound changes in newborns with respiratory distress during provision of CPAP while providing Kangaroo care 
Scientific Title of Study   Comparing Lung Ultrasound (LUS) outcomes in preterm neonates (28 to 36 weeks gestation) on CPAP with and without KMC: A Randomized controlled trial 
Trial Acronym  KULC Trial 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Somashekhar M Nimbalkar 
Designation  Professor 
Affiliation  Bhaikaka University 
Address  Room Number 1. NICU Department of Neonatology Shree Krishna Hospital Pramukhswami medical COllege Gokalnagar Karamsad

Anand
GUJARAT
388325
India 
Phone    
Fax    
Email  somu_somu@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  Hitin CHoudary 
Designation  Resident 
Affiliation  Bhaikaka University 
Address  Room Number 1 Department of Neonatology Shree Krishna Hospital Pramukhswami medical college Karamsad.

Anand
GUJARAT
388325
India 
Phone  9825087842  
Fax    
Email  hitin.choudary@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Somashekhar M Nimbalkar 
Designation  Professor 
Affiliation  Bhaikaka University 
Address  Room No 1 NICU Shree Krishna Hospital Pramukhswami Medical College Gokalnagar

Anand
GUJARAT
388325
India 
Phone    
Fax    
Email  somu_somu@yahoo.com  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Pramukhswami Medical College 
Address  Bhaikaka University Gokalnagar karamsad Anand-Sojitra Road Gujarat, INDIA Pin - 388325 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL   
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Somashekhar Nimbalkar  pramukhswami Medical College  Room number 1 Neonatal NICU, Pramukhswami Medical COllege Karamsad
Anand
GUJARAT 
9825087842

somu_somu@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC2  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: J988||Other specified respiratory disorders,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Kangaroo Mother care on newborns with CPAP with severity being graded with lung ultrasound score and be comparared.  The babies who are having respiratory distress requiring CPAP soon after birth will be kept in KMC and lung ultrasound will be done at birth initially and then it will be done at four hours. KMC is the intervention. 
Comparator Agent  Newborn baby having respiratory distress after birth will receive CPAP as per clinical evaluation with no intervention (Intervention being KMC)  Newborn babies who are having respiratory distress after birth will receive CPAP as per clinical condition and severity will be graded with lung ultrasound score. (No KMC will be given during this time) 
 
Inclusion Criteria  
Age From  1.00 Day(s)
Age To  28.00 Day(s)
Gender  Both 
Details  Preterm neonates with gestational age between 28+0 and 36 weeks.
Requiring CPAP support (initiated in first 24 hours of life) for respiratory distress per unit protocols.
Clinically stable on CPAP defined as: FiO2 less than 0.40, CPAP pressures less than 7 cm H2O, haemodynamically stable (no inotropic support), and no urgent need for intubation at randomization.
Parent/guardian able and willing to provide informed consent and to participate in KMC sessions.
Birth weight more than 900 gm to less than 2.0 kg. 
 
ExclusionCriteria 
Details  1. Major congenital anomalies, including significant congenital lung, cardiac or neurological malformations.
2. Need for immediate intubation or mechanical ventilation at screening.
3. Severe cardiorespiratory instability (requiring inotropes, recurrent severe apnea requiring bag-mask ventilation) at screening
4. Skin conditions or maternal conditions preventing safe KMC (e.g., infectious contraindication in mother).

 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
compare the change in Lung Ultrasound (LUS) score from baseline (within 6 hours of starting CPAP) to 48 hours in preterm neonates randomized to KMC during CPAP versus standard care (CPAP without KMC).  4 hours after intervention starting, then 8 hours and then 12 hours 
 
Secondary Outcome  
Outcome  TimePoints 
1. Compare LUS scores at 4, 8, 12, 24 & 48 hours of life.
2. Compare duration of CPAP support between groups.
3. Compare need for intubation or surfactant therapy within 7 days.
4. Compare oxygen requirement (FiO2) at 4, 8, 12, 24 & 48 hours of life.
5. Compare incidence of bronchopulmonary dysplasia (BPD) at 36 weeks corrected gestation or at discharge.
6. Compare NICU stay duration & in-hospital mortality.
7. Compare rates of hypothermia, apnea, bradycardia, & desaturation during first 72 hours.
8. Record adverse events: accidental CPAP dislodgement, infection/sepsis, & maternal issues.
 
4, 8, 12, 24 & 48 hours of life 
 
Target Sample Size   Total Sample Size="150"
Sample Size from India="150" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   14/02/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

This randomized controlled trial evaluates whether Kangaroo Mother Care (KMC) during CPAP improves lung aeration in preterm neonates, measured by serial lung ultrasound (LUS) scores. The study addresses a significant clinical gap: while KMC is an established low-cost intervention with proven physiological benefits, limited randomized evidence exists comparing LUS-guided outcomes in preterm infants on CPAP with versus without concurrent KMC.

Clinical Rationale

Preterm infants with respiratory distress syndrome require continuous positive airway pressure (CPAP) as the standard non-invasive respiratory support. However, prolonged CPAP carries risks including nasal trauma and feeding delays. KMC, defined as sustained skin-to-skin contact of at least 1 hour per session for a minimum of 4 to 6 hours daily, has demonstrated benefits in reducing apnea, bradycardia, and oxygen desaturation while promoting cardiorespiratory stability. LUS offers a radiation-free, reproducible bedside method for assessing lung aeration and monitoring treatment response. The protocol leverages LUS to objectively quantify whether KMC enhances lung recovery during CPAP support.

Methodology

Study Design: Open-label, two-arm, parallel-group randomized controlled trial with 1:1 allocation conducted over 12 to 18 months at a single NICU center in Gujarat.

Population and Enrollment: The study includes preterm neonates aged 28 to 36 weeks gestation requiring CPAP initiated within 24 hours of life, with birth weights between 900 grams and 2.0 kilograms. Inclusion requires clinical stability (oxygen fraction inspired less than or equal to 0.40, CPAP pressures less than or equal to 7 centimeters H2O, hemodynamic stability) and parental consent. Exclusion criteria include major congenital anomalies, need for immediate intubation, severe cardiorespiratory instability, and maternal contraindications to KMC.

Randomization and Intervention: Computer-generated randomization with sealed opaque envelope allocation assigns participants to either KMC (at least 4 hours daily in at least 1 hour sessions during CPAP) or standard NICU care without KMC. The intervention remains feasible within resource-limited settings, requiring no additional equipment.

Data Collection: Serial LUS assessments occur at baseline (within 6 hours of CPAP initiation), 4, 8, 12, 24, and 48 hours. Concurrent measurements include oxygen requirement (oxygen fraction inspired), vital signs (heart rate, temperature, oxygen saturation), and clinical parameters (episodes of apnea, bradycardia, desaturation). Baseline data capture maternal demographics, antenatal history, neonatal anthropometry, Apgar scores, and clinical diagnosis. Maternal feasibility is evaluated via structured questionnaire.

Primary Outcome: Change in LUS score from baseline to 48 hours between groups.

Secondary Outcomes: LUS scores at intermediate timepoints, CPAP duration, need for intubation or surfactant within 7 days, bronchopulmonary dysplasia at 36 weeks corrected age, NICU stay duration, mortality, incidence of hypothermia and cardiorespiratory events during the first 72 hours, and adverse events (accidental CPAP dislodgement, sepsis, maternal complications).

Statistical Analysis: With an assumed moderate effect size of 50 points difference in LUS score, the study requires 63 participants to achieve 80 percent power at 5 percent type I error. The sample size is increased to 75 participants accounting for 20 percent attrition from death or escalation to mechanical ventilation. Baseline characteristics are summarized descriptively using mean, standard deviation, and frequency percentages. The primary outcome improvement is assessed using paired t-tests and repeated measures designs, with between-group contrasts analyzed using repeated measures analysis of variance or analysis of covariance. Statistical significance is set at p-value less than 0.05 using STATA 19 software.

Ethical Protections

Written informed consent is required from parents. Participant confidentiality is maintained, and treating clinicians retain autonomy in managing complications such as feed intolerance. Publication is planned in indexed journals per institutional guidelines. The protocol requires no external funding.

This methodology addresses a clinically relevant question with appropriate measurement tools (LUS), rigorous randomization, and comprehensive outcome assessment while remaining implementable in resource-constrained neonatal settings.

 
Close